^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
cergutuzumab amunaleukin (RG7813)
i
Other names: RG7813, RO-6895882, RO6895882, RG-7813, CEA-IL2v, CEA IL2v FP, aCEA-IL2v FP
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
Immunostimulant, IL-2 stimulant, CEACAM5 inhibitor
Related drugs:
3ms
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors. (PubMed, Clin Cancer Res)
These preliminary findings suggest that obinutuzumab pretreatment before CEA-IL2v administration in patients with CEA+ solid tumors may be a feasible and potent ADA mitigation strategy, with an acceptable safety profile, supporting broader investigation of obinutuzumab pretreatment for ADA mitigation in other settings.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 positive
|
Tecentriq (atezolizumab) • Rituxan (rituximab) • Gazyva (obinutuzumab) • cergutuzumab amunaleukin (RG7813)
over4years
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
P1b, N=70, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
Clinical • Trial completion
|
CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
Tecentriq (atezolizumab) • cergutuzumab amunaleukin (RG7813)
over4years
Prediction of the optimal dosing regimen using a mathematical model of tumour uptake for immunocytokine-based cancer immunotherapy. (PubMed, Clin Cancer Res)
The model presented here allows simulation of individualized treatment plans for optimal dosing and scheduling of immunocytokines for anti-cancer immunotherapy.
Journal
|
IL2RA (Interleukin 2 receptor, alpha)
|
cergutuzumab amunaleukin (RG7813)
5years
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
P1b, N=70, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Oct 2019 | Trial primary completion date: May 2019 --> Oct 2019
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
Tecentriq (atezolizumab) • cergutuzumab amunaleukin (RG7813)
over5years
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
P1b, N=75, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2018 --> Apr 2019
Clinical • Trial completion date • Trial primary completion date
|
CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression
|
Tecentriq (atezolizumab) • cergutuzumab amunaleukin (RG7813)
Share via
